Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 287

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Chan, Anthony T.C., Hsu, Mow-Ming, Goh, Boon C., Hui, Edwin P., Liu, Tsang-Wu, Millward, Michael J., Hong, Ruey-Long, Whang-Peng, Jacqueline, Ma, Brigette B.Y., To, Ka F., Mueser, Matthias, Amellal, Nadia, Lin, Xiao, Chang, Alex Y.·2005·Journal of Clinical Oncology

Abstract

Purpose: To evaluate efficacy and toxicity of cetuximab plus carboplatin in recurrent or metastatic nasopharyngeal carcinoma (NPC) resistant to platinum treatment. Patients and Methods: A multicenter, open-label, single-arm, phase II study in patients with epidermal growth factor receptor–expressing NPC who progressed on or within 12 months after termination of platinum-based chemotherapy for recurrent or metastatic disease. Cetuximab was administered at an initial dose of 400 mg/m 2 followed by weekly doses of 250 mg/m 2. Carboplatin area under the curve 5 was administered every 3 weeks up to a maximum of eight cycles. Results: Sixty patients were enrolled (46 males, 14 females; median age, 44.5 years; range, 23 to 64 years), and all patients were included in the intent-to-treat and safety analyses. Of the 59 patients assessable for efficacy, there were seven partial responses (11.7%), 29 patients (48.3%) with stable disease, and 23 patients (38.3%) with progressive disease, giving an overall response rate of 11.7% (95% CI, 4.8% to 22.6%). The median time to progression was 81 days in all patients and was longest in the group of patients with a confirmed response (173 days). The median overall survival time was 233 days in all patients. Six patients (10%) experienced serious treatment-related adverse events. Grade 3 or 4 toxicities occurred in 31 patients (51.7%); of these patients, only 19 (31.7%) were considered to have toxicity related to cetuximab. Conclusion: Cetuximab in combination with carboplatin demonstrates clinical activity and an acceptable safety profile in heavily pretreated patients with recurrent or metastatic NPC who had previously experienced treatment failure with platinum-based therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.02.147

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 287

Metadata

Authors
Chan, A. T. C., Hsu, M.-M., Goh, B. C., Hui, E. P., Liu, T.-W., Millward, M. J., Hong, R.-L., Whang-Peng, J., Ma, B. B. Y., To, K. F., Mueser, M., Amellal, N., Lin, X., & Chang, A. Y.
Venue
Journal of Clinical Oncology
Published
2005-05-20
Volume
23
Issue
15
Pages
3568-3576
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2095617994
Cited by
287
References
16
FWCI
17.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2005.02.147
The paper
Chan, A. T. C., Hsu, M.-M., Goh, B. C., Hui, E. P., Liu, T.-W., Millward, M. J., Hong, R.-L., Whang-Peng, J., Ma, B. B. Y., To, K. F., Mueser, M., Amellal, N., Lin, X., & Chang, A. Y. (2005). Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.02.147

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.